Target TMPRSS2, Spike protein

Aus coViki
Wechseln zu: Navigation, Suche

TMPRSS2

GET 2020. Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2). Extract
  • GET 2020. Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection Extract
  • GET ä. Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2 Extract
  • GET 2020. Inhibition of Influenza A virus propagation by benzoselenoxanthenes stabilizing TMPRSS2 Gene G-quadruplex and hence down-regulating TMPRSS2 expression Extract
  • GET 2020. TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention? Extract
  • GET 2020. Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells. Extract
  • GET 2020. Virtual drug repurposing study against SARS-CoV-2 TMPRSS2 target. Extract

any specific other target will be 'parked' here !

  • GET 2020. A human monoclonal antibody blocking SARS-CoV-2 infection Extract
  • GET ä. Human antibodies can neutralize SARS-CoV-2 Extract
  • GET 2020. Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease. Extract
GET 2020. Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA. Extract
  • GET 2020. Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19. Extract

Main coronavirus protease, mPro

  • GET 2020. Potential anti-SARS-CoV-2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease Extract
  • GET 2020. Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design Extract
  • GET ä. Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines Extract
  • GET 2020. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease Extract
  • GET 2020. Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study Extract
  • GET 2020. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved ?-ketoamide inhibitors Extract
  • GET ä. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease Extract
  • GET ä. Insights into the inhibitory potential of selective phytochemicals against Mpro of 2019-nCoV: a computer-aided study Extract
  • GET 2020. In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking Extract
  • GET 2020. Moroccan Medicinal plants as inhibitors against SARS-CoV-2 main protease: Computational investigations Extract
  • GET 2020. Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach Extract
  • GET 2020. Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease Extract
  • GET 2020. Understanding the binding affinity of noscapines with protease of SARS-CoV-2 for COVID-19 using MD simulations at different temperatures Extract
  • GET 2020. Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target Extract
  • GET 2020. FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication Extract
  • GET 2020. An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study Extract
  • GET 2020. A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2 Extract
  • GET ä. Rapid Identification of Potential Inhibitors of SARS?CoV?2 Main Protease by Deep Docking of 1 3?Billion Compounds Extract
  • GET 2020. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors Extract
  • GET 2020. Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1 3 Billion Compounds Extract
  • GET ä. Binding site analysis of potential protease inhibitors of COVID-19 using AutoDock Extract
  • GET 2020. Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition. Extract
  • GET 2020. Potential Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 606 Million Compounds. Extract
  • GET 2020. Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach. Extract
  • GET 2020. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus. Extract
  • GET 2020. Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication. Extract
  • GET 2020. Virtual screening, ADME/T, and binding free energy analysis of anti-viral, anti-protease, and anti-infectious compounds against NSP10/NSP16 methyltransferase and main protease of SARS CoV-2. Extract
  • GET 2020. Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Extract
  • GET 2020. Identification of phytochemical inhibitors against main protease of COVID-19 using molecular modeling approaches. Extract
  • GET 2020. Fragment tailoring strategy to design novel chemical entities as potential binders of novel corona virus main protease. Extract
  • GET 2020. Marine natural compounds as potents inhibitors against the main protease of SARS-CoV-2-a molecular dynamic study. Extract
  • GET 2020. Elucidating biophysical basis of binding of inhibitors to SARS-CoV-2 main protease by using molecular dynamics simulations and free energy calculations. Extract
  • GET 2020. Identification of potential natural inhibitors of SARS-CoV2 main protease by molecular docking and simulation studies. Extract
  • GET 2020. Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy. Extract
  • GET 2020. Triazavirin - Potential inhibitor for 2019-nCoV Coronavirus M protease: A DFT study. Extract
  • GET 2020. Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors. Extract
  • GET 2020. Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: an in silico based approach. Extract
  • GET 2020. Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach. Extract
  • GET 2020. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy. Extract
GET 2020. Statins and the COVID-19 main protease: in silico evidence on direct interaction. Extract
  • GET 2020. Withanone and caffeic acid phenethyl ester are predicted to interact with main protease (M(pro)) of SARS-CoV-2 and inhibit its activity. Extract
  • GET 2020. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M(pro) enzyme through in silico approach. Extract
  • GET 2020. In silico fight against novel coronavirus by finding chromone derivatives as inhibitor of coronavirus main proteases enzyme. Extract
  • GET 2020. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Extract
  • GET 2020. Paromomycin: a potential dual targeted drug effectively inhibits both Spike (S1) and Main Protease of COVID-19. Extract
  • GET 2020. In silico prediction of potential inhibitors for the Main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. Extract
  • GET 2020. Cibler la protease majeure du SARS-CoV-2 pour fabriquer un medicament efficace contre ce coronavirus. Extract
  • GET 2020. Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences. Extract
  • GET 2020. Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target. Extract
  • GET 2020. Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors - an in silico docking and molecular dynamics simulation study. Extract
  • GET 2020. Promising inhibitors of main protease of novel corona virus to prevent the spread of COVID-19 using docking and molecular dynamics simulation. Extract
  • GET 2020. In silico identification of potential inhibitors from Cinnamon against main protease and spike glycoprotein of SARS CoV-2. Extract
  • GET 2020. Constituents of buriti oil (Mauritia flexuosa L.) like inhibitors of the SARS-Coronavirus main peptidase: an investigation by docking and molecular dynamics. Extract
  • GET 2020. Discovery of alliin as a putative inhibitor of the main protease of SARS-CoV-2 by molecular docking. Extract
  • GET 2020. Synthesis, Spectroscopic Characterizations of Novel Norcantharimides, Their ADME Properties and Docking Studies Against COVID-19 M(pr) degrees . Extract
  • GET 2020. Interaction of the prototypical alpha-ketoamide inhibitor with the SARS-CoV-2 main protease active site in silico: Molecular dynamic simulations highlight the stability of the ligand-protein complex. Extract
  • GET 2020. Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19. Extract
  • GET 2020. Combined drug repurposing and virtual screening strategies with molecular dynamics simulation identified potent inhibitors for SARS-CoV-2 main protease (3CLpro). Extract
  • GET 2020. An in silico approach for identification of novel inhibitors as potential therapeutics targeting COVID-19 main protease. Extract
  • GET 2020. Computational Determination of Potential Inhibitors of SARS-CoV-2 Main Protease. Extract
  • GET 2020. Fragment Molecular Orbital Based Interaction Analyses on COVID-19 Main Protease - Inhibitor N3 Complex (PDB ID: 6LU7). Extract

3CL hydrolase-protease,3C-like proteinase, 3CLpro, 3-chymotrypsin-like protease, 3CL(pro)

  • GET 2020. Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes Extract
  • GET 2020. Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2?-O-ribose methyltransferase Extract
  • GET 2020. 3CLpro inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials Extract
  • GET ä. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants? Extract
  • GET ä. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease Extract
  • GET 2020. Structural Basis for Inhibiting Porcine Epidemic Diarrhea Virus Replication with the 3C-Like Protease Inhibitor GC376 Extract
  • GET 2019. Identification of novel proteolytically inactive mutations in coronavirus 3C-like protease using a combined approach Extract
  • GET 2020. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL(pro)): an in silico screening of alkaloids and terpenoids from African medicinal plants Extract
  • GET 2020. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach Extract
  • GET ä. Binding site analysis of potential protease inhibitors of COVID-19 using AutoDock Extract
  • GET 2020. Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors. Extract
  • GET 2020. Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL(pro). Extract
  • GET 2020. Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases. Extract
  • GET 2020. In silico analysis and identification of promising hits against 2019 novel coronavirus 3C-like main protease enzyme. Extract
  • GET 2020. Identification of a novel dual-target scaffold for 3CLpro and RdRp proteins of SARS-CoV-2 using 3D-similarity search, molecular docking, molecular dynamics and ADMET evaluation. Extract
  • GET 2020. Discovery of New Hydroxyethylamine Analogs against 3CL(pro) Protein Target of SARS-CoV-2: Molecular Docking, Molecular Dynamics Simulation, and Structure-Activity Relationship Studies. Extract

PLpro papain-like protease

  • GET 2020. Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some in-house molecules as papain-like protease (PLpro) inhibitors. Extract
  • GET 2020. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease. Extract


Envelope protein ion channel

  • GET 2020. In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel Extract

2alpha-O-ribose methyltransferase

  • GET 2020. Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2?-O-ribose methyltransferase Extract


Deubiquinases'

  • GET 2020. Deubiquitinating Enzymes in Coronaviruses and Possible Therapeutic Opportunities for COVID-19. Extract

Helicase

  • GET 2020. State-of-the-art tools unveil potent drug targets amongst clinically approved drugs to inhibit helicase in SARS-CoV-2. Extract
GET 2020. The G-Quadruplex/Helicase World as a Potential Antiviral Approach Against COVID-19. Extract
  • GET 2020. Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy? Extract

nsp10 RNA polymerase

  • AV Remdesivir
  • GET 2020. Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2. Extract
  • GET 2020. Natural RNA dependent RNA polymerase inhibitors: Molecular docking studies of some biologically active alkaloids of Argemone mexicana. Extract
  • GET 2020. SARS-CoV-2 RNA polymerase as target for antiviral therapy Extract
  • GET ä. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study Extract
  • GET 2020. Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs Extract
  • GET 2020. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective Extract
  • GET 2020. Halting coronavirus polymerase Extract
  • GET 2020. SARS-CoV-2 and SARS-CoV: Virtual Screening of Potential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12). Extract

nsp10 nsp16 methytransferase

  • GET 2020. Virtual screening, ADME/T, and binding free energy analysis of anti-viral, anti-protease, and anti-infectious compounds against NSP10/NSP16 methyltransferase and main protease of SARS CoV-2. Extract
  • GET 2020. Targeting SARS-COV-2 non-structural protein 16: a virtual drug repurposing study. Extract

Nsp14 cap guanine-N7 methyltransferase

  • GET 2020. Structure-based virtual screening and molecular dynamics simulation of SARS-CoV-2 Guanine-N7 methyltransferase (nsp14) for identifying antiviral inhibitors against COVID-19. Extract
  • GET 2020. Synthesis of adenine dinucleosides SAM analogs as specific inhibitors of SARS-CoV nsp14 RNA cap guanine-N7-methyltransferase. Extract

NSP15

  • GET 2020. An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets Extract
  • GET 2020. Identification of bioactive compounds from Glycyrrhiza glabra as possible inhibitor of SARS-CoV-2 spike glycoprotein and non-structural protein-15: a pharmacoinformatics study. Extract

N-Protein, nucleocapsid phosphoprotein

  • GET 2020. In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain) Extract
  • GET 2020. Virtual screening and dynamics of potential inhibitors targeting RNA binding domain of nucleocapsid phosphoprotein from SARS-CoV-2. Extract
Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge